Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug-Sep;20(6):321-33.
doi: 10.1093/pch/20.6.321.

Preventing hospitalizations for respiratory syncytial virus infection

[Article in English, French]
Joan L Robinson, Nicole Le Saux; Canadian Paediatric Society, Infectious Diseases and Immunization Committee

Preventing hospitalizations for respiratory syncytial virus infection

[Article in English, French]
Joan L Robinson et al. Paediatr Child Health. 2015 Aug-Sep.

Abstract
in English, French, French

Respiratory syncytial virus infection is the leading cause of lower respiratory tract infections in young children. Palivizumab has minimal impact on RSV hospitilization rates as it is only practical to offer it to the highest risk groups. The present statement reviews the published literature and provides updated recommendations regarding palivizumab use in children in Canada.

Le virus respiratoire syncytial est la principale cause d’infection des voies respiratoires inférieures chez les jeunes enfants. Le palivizumab a un effet minime sur le taux d’hospitalisation pour le virus respiratoire syncytial, sauf dans les groupes les plus à risque. Le présent document de principes vise à analyser les publications scientifiques et à formuler des recommandations à jour sur l’utilisation du palivizumab chez les enfants du Canada.

Le virus respiratoire syncytial est la principale cause d’infection des voies respiratoires inférieures chez les jeunes enfants. Le palivizumab a un effet minime sur le taux d’hospitalisation pour le virus respiratoire syncytial, sauf dans les groupes les plus à risque. Le présent document de principes vise à analyser les publications scientifiques et à formuler des recommandations à jour sur l’utilisation du palivizumab chez les enfants du Canada.

Keywords: At-risk infants; Chronic lung disease; Congenital heart disease; Palivizumab; Prematurity; Prophylaxis; RSV.

PubMed Disclaimer

Figures

Figure 1)
Figure 1)
Percentage of proven respiratory syncytial virus (RSV) hospitalizations in children with congenital heart disease who were not given palivizumab arranged according to the year that data collection ended. At study entry, children were up to 12 months(26), 24 months(10,21,25,27) or 36 months(23) of age. For the study from Sweden,(26) the number of children with congenital heart disease was estimated
Figure 2)
Figure 2)
Incidence of proven respiratory syncytial virus (RSV) hospitalizations per 1000 children with chronic lung disease of prematurity who were not given palivizumab, presented according to age at the time of the study. The bars represent 95% CIs (except for reference , in which raw data were not provided). For the study from Sweden(26), the number of children with chronic lung disease of prematurity was estimated
Figure 3)
Figure 3)
Incidence of proven respiratory syncytial virus (RSV) hospitalizations per 1000 preterm children without chronic lung disease of prematurity who were not given palivizumab, arranged according to gestational age. The bars represent 95% CIs. RSV testing was not performed in 38 of 118 admissions in reference . *The upper limit of the 95% CI is 42.9
See this image and copyright information in PMC

References

    1. Tan B, Canadian Paediatric Society. Infectious Diseases and Immunization Committee Palivizumab and respiratory syncytial virus globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Paediatr Child Health. 1999;4(7):474–80. - PMC - PubMed
    1. Langley JM, Canadian Paediatric Society. Infectious Diseases and Immunization Committee Use of palivizumab in children with congenital heart disease. Paediatr Child Health. 2003;8(10):631–3. - PMC - PubMed
    1. Sampson L, Canadian Paediatric Society. Infectious Diseases and Immunization Committee Prevention of respiratory syncytial virus infection. Paediatr Child Health. 2009;14(8):521–6. - PMC - PubMed
    1. Robinson JL, Canadian Paediatric Society. Infectious Diseases and Immunization Committee Preventing respiratory syncytial virus infections. Paediatr Child Health. 2011;16(8):487–8. - PMC - PubMed
    1. Jefferson T, Del Mar C, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2010;(1):CD006207. - PubMed

LinkOut - more resources